Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment

• Published in: European journal of gastroenterology & hepatology Vol. 32; no. 9; pp. 1091 - 1098
• Main Authors: Bertani, Lorenzo, Mumolo, Maria Gloria, Tapete, Gherardo, Albano, Eleonora, Baiano Svizzero, Giovanni, Zanzi, Federico, Ceccarelli, Linda, Bellini, Massimo, Marchi, Santino, Costa, Francesco
• Format: Journal Article
• Language: English
• Published: England Wolters Kluwer Health, Inc. All rights reserved 01-09-2020; Copyright Wolters Kluwer Health, Inc. All rights reserved
• ISSN: 0954-691X; 1473-5687
• DOI: 10.1097/MEG.0000000000001731

Fecal calprotectin has been widely studied in inflammatory bowel disease (IBD) under clinical and therapeutic settings. It showed a good correlation with clinical, endoscopic, and histologic findings. For these reasons, fecal calprotectin is currently one of the most useful tools in IBD care, both in diagnosis and in clinical management. The development of biologic drugs allowed a deeper control of disease, which sometimes reaches histological healing; this is associated with a reduced risk of relapses and complications. The management of IBD treatment is currently carried out with a treat-to-target approach, and mucosal healing is considered at present to be the optimal therapeutic target, but the future is going through histologic remission. Fecal calprotectin is probably the best marker of mucosal healing, but it is correlated also with histologic remissionmoreover, it has been recently studied as a possible therapeutic target in the CALM study. We carried out a comprehensive literature review in order to evaluate the role of fecal calprotectin at present and in the future in the management of IBD therapies.